A Phase 1 interventional study of Esketamine DPI and Esketamine DPI in Healthy Volunteers, sponsored by Celon Pharma SA. Completed at 1 site in Poland. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-12.
Sponsored by Celon Pharma SA · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The planned study is to determine the pharmacokinetic properties of Esketamine and safety assessment with inhaled Esketamine after different number of inhalations and different dosing sequences within three parts of the study.
This is to be one-centre, single ascending dose and double-blind placebo controlled multiple dose three part study of Esketamine DPI (dry powder inhaler) in healthy volunteers.
PART A is a single dose, open-label part with Esketamine DPI inhalations administered with dose escalation between cohorts.
PART B is a single dose, open-label part with Esketamine DPI inhalations administered in different dosing sequences with dose escalation between cohorts.
PART C is a multiple dose, double-blind, placebo-controlled part with Esketamine DPI inhalations administered in different cycles of treatment (with four dosing sequences within two weeks) with dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.
Pharmacokinetic properties and safety of Esketamine DPI will be determined following different number of inhalations in PART A, different dosing sequences in PART B and different cycles of treatment in PART C.
Celon Pharma SA is the lead sponsor of 11 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.
Drug: Esketamine DPI
4 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.
Drug: Esketamine DPI
4 cohorts will receive multiple dose of Esketamine DPI in two weeks' time administered with dose escalation between cohorts.
Drug: Esketamine DPI
4 cohorts will receive multiple dose of matching placebo in two weeks' time.
Drug: Placebo DPI
Participants will receive different number of consecutive Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts.
Participants will receive different dosing sequences of Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A of the study. Dose: very low, low, medium, high.
Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. There will be dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A and PART B of the study. Dose: very low, low, medium, high.
Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations.
Cmax - maximum Esketamine plasma concentration
The maximum concentration of the Esketamine in plasma after drug administration, obtained directly from the measured concentrations.
Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.
AUC (0-24) - area under the Esketamine plasma concentration-time curve from time 0 to 24 hours after study drug administration
The AUC(0-24) is a measure of total plasma exposure to the drug from time point zero to 24 hours after study drug administration.
Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.
Number of inhalations needed to achieve the assumed Esketamine antidepressive plasma concentration.
Time frame: up to 24 hours after study drug administration in PART A
Number of inhalations within dosing sequence needed to maintain the assumed Esketamine antidepressive plasma concentration.
Time frame: up to 24 hours after study drug administration in PART B
AUC (0-inf) - area under the Esketamine plasma concentration-time curve from time 0 to infinity time
The AUC(0-inf) is a measure of total plasma exposure to the drug from time point zero extrapolated to infinity.
Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.
Tmax - time to reach maximum Esketamine plasma concentration
The Tmax is time to reach the maximum plasma concentration (Cmax), obtained directly from the actual sampling times.
Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.
Kel -elimination rate constant
Kel will be estimated via linear regression of time versus log of concentration.
Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.
T1/2 - plasma elimination half-life for Esketamine
T1/2 will be calculated as 0.693/Kel.
Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.
Cmax - maximum Esnorketamine plasma concentration
The maximum concentration of the Esnorketamine in plasma after drug administration, obtained directly from the measured concentrations. Esnorketamine is Esketamine's main metabolite.
Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.
AUC (0-24) - area under the Esnorketamine plasma concentration-time curve from time 0 to 24 hours after study drug administration.
The AUC(0-24) is a measure of total Esnorketamine plasma exposure to the metabolite from time point zero to 24 hours after study drug administration. Esnorketamine is Esketamine's main metabolite.
Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.
Tmax - time to reach maximum Esnorketamine plasma concentration.
The Tmax is time to reach the maximum Esnorketamine plasma concentration (Cmax), obtained directly from the actual sampling times. Esnorketamine is Esketamine's main metabolite.
Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.
Number of participants with adverse events (AEs) and Serious Adverse Events (SAEs).
Participants during hospitalization will be closely observed to assure maximal safety and to collect occurrence of all adverse event. To follow-up on all study participants telephone calls with a request for information regarding their health condition will be made. All adverse events will be collected with special attention to occurrence of psychotomimetic and dissociative effects after study drug administration.
Time frame: up to 7 days in PART A and PART B of the study and up to 25 days in PART C of the study.
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2017 to primary completion in May 2018, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Celon Pharma SA